S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Not Recruiting

Trial ID: NCT03091660


This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.

Official Title

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer

Stanford Investigator(s)

Eila C. Skinner
Eila C. Skinner

Thomas A. Stamey Research Professor of Urology

Benjamin I. Chung
Benjamin I. Chung

Associate Professor of Urology

Harcharan Gill
Harcharan Gill

Kathryn Simmons Stamey Professor, Emeritus


Inclusion Criteria:

   - Patients must have histologically proven Ta, carcinoma in situ (CIS) or T1 stage
   urothelial cell carcinoma of the bladder within 90 days of registration

   - Patients must have had all grossly visible papillary tumors removed within 30 days
   prior to registration or cystoscopy confirming no grossly visible papillary tumors
   within 30 days prior to registration

   - Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis
   demonstrating no evidence of metastatic disease (magnetic resonance imaging [MRI] or
   computed tomography [CT] scan) within 90 days prior to registration; patients with T1
   disease must have re-resection confirming =< T1 disease within 90 days prior to

   - Patients must have high-grade bladder cancer as defined by 2004 World Health
   Organization (WHO)/International Society of Urological Pathology (ISUP) classification

   - Patients must not have pure squamous cell carcinoma or adenocarcinoma

   - Patients' disease must not have micropapillary components

   - Patients must have no evidence of upper tract (renal pelvis or ureters) cancer
   confirmed by one of the following tests performed within 90 days prior to
   registration: CT urogram, intravenous pyelogram, magnetic resonance (MR) urogram, or
   retrograde pyelograms

   - Patients must not have nodal involvement or metastatic disease

   - No other prior malignancy is allowed except for the following: adequately treated
   basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
   stage I or II cancer from which the patient is currently in complete remission, or any
   other cancer from which the patient has been disease free for five years; patients
   with localized prostate cancer who are being followed by an active surveillance
   program are also eligible

   - Patients must have a Zubrod performance status of 0-2

   - Patients must not have received prior intravesical BCG

   - Patients must not have known history of tuberculosis

   - Patients must be PPD negative within 90 days prior to registration; PPD negativity is
   defined as < 10 mm diameter induration (palpable, raised hardened area) in the volar
   forearm at 48-72 hours following injection with standard tuberculin dose (5 units, 0.1

   - Patients must be >= 18 years of age

   - Patients must not be taking oral glucocorticoids at the time of registration

   - Patients must not be planning to receive concomitant biologic therapy, hormonal
   therapy, chemotherapy, surgery, or other cancer therapy while on study

   - Prestudy history and physical must be obtained within 90days prior to registration

   - Patients must not be pregnant or nursing; women/men of reproductive potential must
   have agreed to use an effective contraceptive method; a woman is considered to be of
   "reproductive potential" if she has had menses at any time in the preceding 12
   consecutive months; in addition to routine contraceptive methods, "effective
   contraception" also includes heterosexual celibacy and surgery intended to prevent
   pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
   bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
   previously celibate patient chooses to become heterosexually active during the time
   period for use of contraceptive measures outlined in the protocol, he/she is
   responsible for beginning contraceptive measures

   - Patients must be offered the opportunity to participate in specimen banking for future
   studies to include translational medicine studies


biological: BCG Solution

biological: BCG Tokyo-172 Strain Solution

biological: BCG Tokyo-172 Strain Vaccine

other: Laboratory Biomarker Analysis

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.